Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders

Br J Dermatol. 2002 Aug;147(2):385-6. doi: 10.1046/j.1365-2133.2002.48901.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Female
  • HLA-DR Antigens / analysis
  • HLA-DR Serological Subtypes
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Middle Aged
  • Recombinant Proteins
  • Scleroderma, Systemic / etiology*
  • Scleroderma, Systemic / immunology

Substances

  • Antineoplastic Agents
  • HLA-DR Antigens
  • HLA-DR Serological Subtypes
  • HLA-DR11 antigen
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins